Overview
Availability
- Associate Professor David Wyld is:
- Available for supervision
Works
Search Professor David Wyld’s works on UQ eSpace
2010
Journal Article
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study
Tebbutt, Niall C., Wilson, Kate, Gebski, Val J., Cummins, Michelle M., Zannino, Diana, Van Hazel, Guy A., Robinson, Bridget, Broad, Adam, Ganju, Vinod, Ackland, Stephen P., Forgeson, Garry, Cunningham, David, Saunders, Mark P., Stockler, Martin R., Chua, Yujo, Zalcberg, John R., Simes, R. John, Price, Timothy J., Price, Tim, Simes, John, Coates, Alan, O'Connell, Diane, Brown, Chris, Hague, Wendy, France, Alyson, Hicks, Sian, James, Rebecca, Masson, Ruby, O'Connell, Rachel ... Gebbie, Chantal (2010). Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. Journal of Clinical Oncology, 28 (19), 3191-3198. doi: 10.1200/JCO.2009.27.7723
2010
Journal Article
Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme
Francesconi, Alessandra B., Dupre, Simon, Matos, Marco, Martin, David, Hughes, Brett G., Wyld, David K. and Lickliter, Jason D. (2010). Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. Journal of Clinical Neuroscience, 17 (8), 970-974. doi: 10.1016/j.jocn.2009.12.009
2009
Journal Article
Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers
Herbertson, Rebecca A., Tebbutt, Niall C., Lee, Fook-Thean, MacFarlane, David J., Chappell, Bridget, Micallef, Noel, Lee, Sze-Ting, Saunder, Timothy, Hopkins, Wendie, Smyth, Fiona E., Wyld, David K., Bellen, John, Sonnichsen, Daryl S., Brechbiel, Martin W., Murone, Carmel and Scott, Andrew M. (2009). Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clinical Cancer Research, 15 (21), 6709-6715. doi: 10.1158/1078-0432.CCR-09-0536
2009
Journal Article
Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial
Au, Heather-Jane, Karapetis, Christos S., O'Callaghan, Chris J., Tu, Dongsheng, Moore, Malcolm J., Zalcberg, John R., Kennecke, Hagen, Shapiro, Jeremy D., Koski, Sheryl, Pavlakis, Nick, Charpentier, Danielle, Wyld, David, Jefford, Michael, Knight, Gregory J., Magoski, Nadine M., Brundage, Michael D. and Jonker, Derek J. (2009). Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. Journal of Clinical Oncology, 27 (11), 1822-1828. doi: 10.1200/JCO.2008.19.6048
2009
Journal Article
Nesidioblastosis as a cause of focal pancreatic 111In-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosis
Francesconi, Alessandra Bastian, Matos, Marco, Lee, Joseph C., Wyld, David K., Clouston, Andrew D. and Macfarlane, David (2009). Nesidioblastosis as a cause of focal pancreatic 111In-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosis. Annals of Nuclear Medicine, 23 (5), 497-499. doi: 10.1007/s12149-009-0252-6
2008
Conference Publication
Phase I evaluation of CYT997, a novel cytotoxic and vascular-disrupting agent, in patients with advanced cancer
Lickliter, J., Francesconi, A., Smith, G., Burge, M., Coulthard, A., Rose, S., Griffin, M., Wilks, A., Wyld, D. and Vasey, P. (2008). Phase I evaluation of CYT997, a novel cytotoxic and vascular-disrupting agent, in patients with advanced cancer. 2008 ASCO Annual Meeting, Chicago, IL, U.S.A., 30 May - 3 June, 2008. Alexandria, VA. U.S.A.: American Society of Clinical Oncology.
2007
Journal Article
Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial
Stockler, M. R., O'Connell, R., Nowak, A. K., Goldstein, D., Turner, J., Wilcken, N. R. C., Wyld, D., Abdi, E., Glasgow, A., Beale, P. J., Jefford, M., Dhillon, H., Heritier, S., Carter, C., Hickie, I. B. and Simes, R. J. (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. The Lancet Oncology, 8 (7), 603-612. doi: 10.1016/S1470-2045(07)70148-1
2007
Journal Article
Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer
Friedlander, M, Buck, M, Wyld, D, Findlay, M, Fitzharris, B, De Souza, P, Davies, T, Kalimi, G, Allan, S, Perez, D and Harnett, P (2007). Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer. International Journal of Gynecological Cancer, 17 (2), 350-358. doi: 10.1111/j.1525-1438.2007.00795.x
2007
Journal Article
A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma
Kefford, Richard, Beith, Jane McNeil, Van Hazel, Guy Arthur, Millward, Michael, Trotter, James Marshall, Wyld, David Keith, Kusic, Rada, Shreeniwas, Revati, Morganti, Adele, Ballmer, Andrea, Segal, Eleonor, Nayler, Oliver and Clozel, Martine (2007). A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Investigational New Drugs, 25 (3), 247-252. doi: 10.1007/s10637-006-9014-7
2006
Journal Article
Metastatic paraganglioma with extensive bone marrow involvement
Morris, Kirk L., Macfarlane, David, Wyld, David and Kennedy, Glen A. (2006). Metastatic paraganglioma with extensive bone marrow involvement. Asia-Pacific Journal of Clinical Oncology, 2 (4), 193-194. doi: 10.1111/j.1743-7563.2006.00068.x
2005
Conference Publication
Analysis of expression of Eph/Ephrin tyrosine kinases in advanced ovarian cancer.
Sabesan, SS, Wyld, D, Herath, N and Boyd, A (2005). Analysis of expression of Eph/Ephrin tyrosine kinases in advanced ovarian cancer.. 41st Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando Fl, May 13-17, 2005. AMER SOC CLINICAL ONCOLOGY.
2005
Conference Publication
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage TV metastatic melanoma
Kefford, R, Beith, J, Van Hazel, GA, Millward, M, Trotter, J, Wyld, D, Kusic, R, Coward, J, Shreeniwas, R and Morganti, A (2005). A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage TV metastatic melanoma. ESMO Scientific and Educational Conference (ESEC), Budapest Hungary, Jun 02-05, 2005. OXFORD: OXFORD UNIV PRESS.
2004
Journal Article
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
Le Chevalier, T., Arriagada, R., Le Pechoux, C., Grunenwald, D., Dunant, A., Pignon, J. P., Tarayre, M., Abratt, R., Arriagada, R., Bergman, B., Gralla, R., Grunenwald, D., Le Chevalier, T., Orlowski, T., Papadakis, E., Pinel, M. I. Sathler, Araujo, C., Della Torre, H., de Solchaga, M. Masetto, Abdi, E., Blum, R., Ball, D., Basser, R., De Boer, R., Bishop, J., Brigham, B., Davis, S., Fox, D., Richardson, G. ... Wedel, H. (2004). Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New England Journal of Medicine, 350 (4), 351-360. doi: 10.1056/NEJMoa031644
2000
Journal Article
Conquering chemotherapy
Horwood, Keith and Wyld, David (2000). Conquering chemotherapy. Australian Prescriber, 23 (3).
2000
Journal Article
Conquering chemotherapy [3] (multiple letters)
Allison, R., Horwood, K. and Wyld, D. (2000). Conquering chemotherapy [3] (multiple letters). Australian Prescriber, 23 (3).
2000
Journal Article
Cisplatin-based therapy: A neurological and neuropsychological review
Troy, L., McFarland, K., Littman-Power, S., Kelly, B.J., Walpole, E.T., Wyld, D. and Thomson, D. (2000). Cisplatin-based therapy: A neurological and neuropsychological review. Psycho-oncology, 9 (1), 29-39. doi: 10.1002/(SICI)1099-1611(200001/02)9:1
2000
Journal Article
Cisplatin-based therapy: A neurological and neurophysical review
Troy, L., McFarland, K. A., Littman-Powers, S., Kelly, B. J., Walpole, E. T., Wyld, D. and Thomson, D. (2000). Cisplatin-based therapy: A neurological and neurophysical review. Psychooncology, 9 (1), 29-39. doi: 10.1002/(SICI)1099-1611(200001/02)9:1
1999
Book Chapter
The impact of Cisplatin-based chemotherapy on everyday attention
Troy, L., Littmann-Power, S. C., Kelly, B. J., Thomson, D. and Wyld, D. (1999). The impact of Cisplatin-based chemotherapy on everyday attention. Brain Impairment and Rehabilitation: A National Perspective. (pp. 140-142) Brisbane: Aust. Academic Press.
1998
Journal Article
Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20
Wyld, DK, Selby, P, Perren, TJ, Jonas, SK, Allen-Mersh, TG, Wheeldon, J and Burchill, SA (1998). Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20. International Journal of Cancer, 79 (3), 288-293. doi: 10.1002/(SICI)1097-0215(19980619)79:33.3.CO;2-2
1998
Journal Article
Endocrine aspects of the clinical management of breast cancer - Current issues
Wyld, DK, Chester, JD and Perren, TJ (1998). Endocrine aspects of the clinical management of breast cancer - Current issues. Endocrine-Related Cancer, 5 (2), 97-110. doi: 10.1677/erc.0.0050097
Supervision
Availability
- Associate Professor David Wyld is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Examining real-world evidence for immune checkpoint inhibitor (PD-L1) treatment in advanced non small cell lung cancer (NSCLC): A population based data analysis in Queensland, Australia
Associate Advisor
Other advisors: Professor Jason Pole
Completed supervision
-
2020
Master Philosophy
Predictors of dosimetry and outcome to peptide receptor radionuclide therapy in metastatic neuroendocrine tumour.
Principal Advisor
Other advisors: Associate Professor David Pattison
-
2021
Doctor Philosophy
Targeting receptor activator of NF-kB pathways in combination immunotherapy
Associate Advisor
Media
Enquiries
For media enquiries about Associate Professor David Wyld's areas of expertise, story ideas and help finding experts, contact our Media team: